Terms: = Germ cell tumor AND PIM1, PIM, 5292, ENSG00000137193, P11309 AND Treatment
18 results:
1. DNA methylation heterogeneity attributable to a complex tumor immune microenvironment prompts prognostic risk in glioma.
Ma S; Pan X; Gan J; Guo X; He J; Hu H; Wang Y; Ning S; Zhi H
Epigenetics; 2024 Dec; 19(1):2318506. PubMed ID: 38439715
[TBL] [Abstract] [Full Text] [Related]
2. Metabolic protein kinase signalling in neuroblastoma.
Smiles WJ; Catalano L; Stefan VE; Weber DD; Kofler B
Mol Metab; 2023 Sep; 75():101771. PubMed ID: 37414143
[TBL] [Abstract] [Full Text] [Related]
3. Inhibition of pim Kinases Promotes Neuroblastoma cell Differentiation to a Neuronal Phenotype.
Julson JR; Quinn CH; Bownes LV; Hutchins SC; Stewart JE; Aye J; Yoon KJ; Beierle EA
J Pediatr Surg; 2023 Jun; 58(6):1155-1163. PubMed ID: 36907773
[TBL] [Abstract] [Full Text] [Related]
4. The clinical and molecular characteristics of progressive hypothalamic/optic pathway pilocytic astrocytoma.
Li X; Moreira DC; Bag AK; Qaddoumi I; Acharya S; Chiang J
Neuro Oncol; 2023 Apr; 25(4):750-760. PubMed ID: 36260562
[TBL] [Abstract] [Full Text] [Related]
5. Endoscopic versus Nonendoscopic Surgery for Resection of Craniopharyngiomas.
Abiri A; Roman KM; Latif K; Goshtasbi K; Torabi SJ; Lehrich BM; Mohyeldin A; Hsu FPK; Kuan EC
World Neurosurg; 2022 Nov; 167():e629-e638. PubMed ID: 36041722
[TBL] [Abstract] [Full Text] [Related]
6. Quercetin increases mitochondrial proteins (VDAC and SDH) and downmodulates AXL and pim-1 tyrosine kinase receptors in NRAS melanoma cells.
Rocha-Brito KJP; Clerici SP; Cordeiro HG; Scotá Ferreira AP; Barreto Fonseca EM; Gonçalves PR; Abrantes JLF; Milani R; Massaro RR; Maria-Engler SS; Ferreira-Halder CV
Biol Chem; 2022 Feb; 403(3):293-303. PubMed ID: 34854272
[TBL] [Abstract] [Full Text] [Related]
7. pim1 Inhibition Affects Glioblastoma Stem cell Behavior and Kills Glioblastoma Stem-like cells.
Seifert C; Balz E; Herzog S; Korolev A; Gaßmann S; Paland H; Fink MA; Grube M; Marx S; Jedlitschky G; Tzvetkov MV; Rauch BH; Schroeder HWS; Bien-Möller S
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681783
[TBL] [Abstract] [Full Text] [Related]
8. Identification of pimavanserin tartrate as a potent Ca
Liu ZZ; Liu XN; Fan RC; Jia YP; Zhang QK; Gao XQ; Wang YQ; Yang MQ; Ji LZ; Zhou YQ; Li HL; Li P; Tang B
Acta Pharmacol Sin; 2021 Nov; 42(11):1860-1874. PubMed ID: 34363007
[TBL] [Abstract] [Full Text] [Related]
9. The targetable kinase pim1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
Trigg RM; Lee LC; Prokoph N; Jahangiri L; Reynolds CP; Amos Burke GA; Probst NA; Han M; Matthews JD; Lim HK; Manners E; Martinez S; Pastor J; Blanco-Aparicio C; Merkel O; de Los Fayos Alonso IG; Kodajova P; Tangermann S; Högler S; Luo J; Kenner L; Turner SD
Nat Commun; 2019 Nov; 10(1):5428. PubMed ID: 31780656
[TBL] [Abstract] [Full Text] [Related]
10. Anti-tumor effects of pim/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.
Mohlin S; Hansson K; Radke K; Martinez S; Blanco-Apiricio C; Garcia-Ruiz C; Welinder C; Esfandyari J; O'Neill M; Pastor J; von Stedingk K; Bexell D
EMBO Mol Med; 2019 Aug; 11(8):e10058. PubMed ID: 31310053
[TBL] [Abstract] [Full Text] [Related]
11. pim Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.
Brunen D; de Vries RC; Lieftink C; Beijersbergen RL; Bernards R
Mol Cancer Ther; 2018 Apr; 17(4):849-857. PubMed ID: 29440296
[TBL] [Abstract] [Full Text] [Related]
12. [Primary intramedullary melanoma: Case report and literature review].
Narváez-Martínez Y; de la Ossa N; López-Martos R; Cohn-Reinoso C; Castellví-Juan M; Martin-Ferrer S
Neurocirugia (Astur); 2017; 28(4):190-196. PubMed ID: 28237771
[TBL] [Abstract] [Full Text] [Related]
13. Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells.
Frömberg A; Rabe M; Oppermann H; Gaunitz F; Aigner A
BMC Cancer; 2017 Jan; 17(1):3. PubMed ID: 28049521
[TBL] [Abstract] [Full Text] [Related]
14. pim kinases as therapeutic targets against advanced melanoma.
Shannan B; Watters A; Chen Q; Mollin S; Dörr M; Meggers E; Xu X; Gimotty PA; Perego M; Li L; Benci J; Krepler C; Brafford P; Zhang J; Wei Z; Zhang G; Liu Q; Yin X; Nathanson KL; Herlyn M; Vultur A
Oncotarget; 2016 Aug; 7(34):54897-54912. PubMed ID: 27448973
[TBL] [Abstract] [Full Text] [Related]
15. Targeting of glioblastoma cell lines and glioma stem cells by combined pim kinase and PI3K-p110α inhibition.
Iqbal A; Eckerdt F; Bell J; Nakano I; Giles FJ; Cheng SY; Lulla RR; Goldman S; Platanias LC
Oncotarget; 2016 May; 7(22):33192-201. PubMed ID: 27120806
[TBL] [Abstract] [Full Text] [Related]
16. Assessment of tumor hypoxia and interstitial fluid pressure by gadomelitol-based dynamic contrast-enhanced magnetic resonance imaging.
Gulliksrud K; Hompland T; Galappathi K; Rofstad EK
Radiother Oncol; 2011 Oct; 101(1):217-22. PubMed ID: 21840612
[TBL] [Abstract] [Full Text] [Related]
17. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract] [Full Text] [Related]
18. Autologous bone marrow transplantation in children with advanced neuroblastoma.
Mugishima H; Iwata M; Okabe I; Sanuki E; Onuma N; Fujimoto T; Ohira M; Kaneko M; Tsuchida Y; Okuni M
Cancer; 1994 Aug; 74(3):972-7. PubMed ID: 8039127
[TBL] [Abstract] [Full Text] [Related]
